ExpreS2ion will participate at key industry and investor events in March 2021
ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate and hold presentations at key industry and investor events in March, all of which will be held digitally. These include Aktiespararna’s Aktiedagen (March 16), the St. Gallen International Breast Cancer Conference (March 17-21), and BIO-Europe Spring (March 22-25).
By attending relevant industry and investor events, the company aims to increase the awareness of the ExpreS2 technology platform and its exciting development pipeline, including the novel ES2B-C001 HER2-cVLP breast cancer vaccine. More information on each event and how to register is found below.
Aktiespararna’s Aktiedagen, March 16, at 11.00-11.30
See the company presentation by our CEO Bent U. Frandsen at this investor event. It is possible to follow the event online, or attend the meeting by reserving a seat at Aktiespararna's website.
17th St. Gallen International Breast Cancer Conference, March 17-21
To learn more about the preclinical-stage ES2B-C001 HER2-cVLP breast cancer vaccine, pre-arrange meetings via email on info@expreS2ionbio.com. More information is available at the event website.
BIO-Europe Spring, March 22-25, Digital
To pre-arrange business meetings with ExpreS2ion representatives, please contact us via email on info@expreS2ionbio.com. More information is available at BIO-Europe’s website.
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
For further information about ExpreS2ion Biotech Holding AB, please contact:
Bent U. Frandsen, CEO
Telephone: +45 4256 6869
ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. ExpreS2ion has developed a unique technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 300 proteins and 40 virus-like particles (VLPs) in collaboration with leading research institutions and companies. Since 2017, ExpreS2ion develops novel VLP based vaccines through its joint venture AdaptVac ApS. For additional information, please visit www.expres2ionbio.com and www.adaptvac.com.